Outsourcing is no longer limited to cost reduction. Pharmaceutical companies are now seeking strategic alliances, agility, and innovation, focusing on long-term cooperation, shared risk, and early CMO involvement. As an example of this trend, Bora Pharmaceuticals and GSK announced in February 2026 a five-year collaboration covering more than 20 products in North America: supply chain resilience and joint quality governance, going beyond simply reducing unit costs.
PHARMAP 2026 It offers a platform for a key debate in the sector: how leading pharmaceutical companies are redefining outsourcing. This year, the "Leaders' Talks" session analyzes the strategic shift from transactional supplier relationships to collaborative partnerships with CDMOs and CMOs.
Presentation at PHARMAP 2026: Henk Mollee, Astellas Pharma Europe BV
As part of the PHARMAP 2026 program, Henk Mollee (CMO Director at Astellas Pharma Europe BV) will present insights into the evolution of alliances through plant divestment. He will analyze how the transition from internal manufacturing assets to external partners requires cultural adaptation, transparent governance, and co-creation of value. Participants will learn methods for building trust-based alliances that balance quality assurance with strategic flexibility.
PHARMAP 2026 Speakers: NTC Pharma, Bayer and Abdi Ibrahim Pharmaceuticals
Following the in-depth presentation by Astellas Pharma Europe, other industry leaders share their strategies:
● Ulrich Rümenapp, Senior Director of Bayer's Biotechnology Program, talks about leveraging external partners for CMC development and GMP manufacturing of biological products as a strategic growth driver;
● Silvia Regondi, Director of Operations at NTC Pharma, on how to forge successful strategic alliances between pharmaceutical companies and their manufacturing partners;
● Buket Işık Uzunoğlu, Director of Contract Manufacturing at Abdi Ibrahim Pharmaceuticals, on how to transform relationships with contract manufacturers (CMOs) from mere supplier transactions to a strategic collaboration.
A new framework for networking
PHARMAP 2026 combines expert-led sessions with structured networking opportunities. The format facilitates the practical application of the collaborative models discussed, fostering peer exchange and direct interaction with the speakers.
Participate in the PHARMAP 2026 dialogue: https://sh.bgs.group/44l
